Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Benchmark Reiterates Buy on Belite Bio, Maintains $80 Price Target

Author: Benzinga Newsdesk | March 26, 2025 10:22am
Benchmark analyst Bruce Jackson reiterates Belite Bio (NASDAQ:BLTE) with a Buy and maintains $80 price target.

Posted In: BLTE

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist